Cubist Pharmaceuticals Inc. is working to combat a group of bacteria largely neglected by drugmakers with a medicine analysts say may have $2 billion in sales potential.
The drug, CXA-201, last month entered the final stage of tests generally required for U.S. approval and is about a year ahead of rivals under development. It aims at a difficult-to- treat family of bacteria, called gram-negatives, that are developing resistance to existing medicines and spreading among hospital patients, said Arjun Srinivasan, of the U.S. Centers for Disease Control and Prevention.
Click "source for entire article.
Related press release: "Cubist Antibiotic Programs Featured in 49 Presentations at 51st ICAAC" (http://www.marketwatch.com/story/cubist-antibiotic-programs-featured-in-49-presentations-at-51st-icaac-2011-09-15)
The drug, CXA-201, last month entered the final stage of tests generally required for U.S. approval and is about a year ahead of rivals under development. It aims at a difficult-to- treat family of bacteria, called gram-negatives, that are developing resistance to existing medicines and spreading among hospital patients, said Arjun Srinivasan, of the U.S. Centers for Disease Control and Prevention.
Click "source for entire article.
Related press release: "Cubist Antibiotic Programs Featured in 49 Presentations at 51st ICAAC" (http://www.marketwatch.com/story/cubist-antibiotic-programs-featured-in-49-presentations-at-51st-icaac-2011-09-15)
